



Cell Therapeutics, Inc.
Making cancer more treatable®

Guide to Presentations at ASH 2007

ZEVALIN®

Date/Time	Abstract #	Presentation/ Poster #	Title
Sunday Dec. 9, 2007 5:15 PM	22	Oral Session	⁹⁰ Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study.
Sunday Dec. 9, 2007 5:15 PM	124	Oral Session	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).
Monday Dec. 10, 2007 12:00 PM	389	Oral Session	Phase II Study of R-CHOP Followed by ⁹⁰ Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.
Monday Dec. 10, 2007 2:00 PM	525	Oral Session	Rituximab Blocks Binding of Radiolabeled Anti-CD20 Antibodies (Ab) but Not Radiolabeled Anti-CD45-Ab.
Monday Dec. 10, 2007 3:45 PM	620	Oral Session	Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.
Monday Dec. 10, 2007 3:30 PM	643	Oral Session	⁹⁰ Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.
Saturday Dec. 8, 2007 5:30 PM	1082	#236-I	The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

*CTI has entered into an agreement to acquire ZEVALIN from Biogen Idec, Inc. Completion of that acquisition is subject to certain closing conditions, including obtaining third-party consents. CTI expects to complete the acquisition in the fourth quarter of 2007, at which time CTI will acquire the rights to develop, market, and sell ZEVALIN in the United States. Until CTI's acquisition of ZEVALIN is completed, both the product and the registered trademark ZEVALIN are owned by Biogen Idec, Inc.



Saturday Dec. 8, 2007 5:30 PM	1360	#514-I	A Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine Plus Mitoxantrone Followed by Yttrium-90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin®) and Maintenance Rituximab as Front Line Therapy for Patients with Intermediate or High Risk Follicular Non-Hodgkin's Lymphoma.
Sunday Dec. 9, 2007 6:00 PM	1890	#80-II	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.
Sunday Dec. 9, 2007 6:00 PM	1891	#81-II	Updated Results of High-Dose Yttrium 90 (⁹⁰ Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AH SCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin's Lymphoma.
Sunday Dec. 9, 2007 6:00 PM	1914	#104-II	Multicenter Phase II Trial of ⁹⁰ Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractory, or High-Risk B-Cell NHL.
Sunday Dec. 9, 2007 6:00 PM	2558	#748-II	A Phase I/II Trial of Radioimmunotherapy (RIT) with ⁹⁰ Yttrium-Ibritumomab Tiuxetan (Zevalin®); ⁹⁰ Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma (NHL).
Monday Dec. 10, 2007 5:00 PM	3059	#278-III	Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study.
Monday Dec. 10, 2007 5:00 PM	3319	#538-III	Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with ⁹⁰ Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).

*CTI has entered into an agreement to acquire ZEVALIN from Biogen Idec, Inc. Completion of that acquisition is subject to certain closing conditions, including obtaining third-party consents. CTI expects to complete the acquisition in the fourth quarter of 2007, at which time CTI will acquire the rights to develop, market, and sell ZEVALIN in the United States. Until CTI's acquisition of ZEVALIN is completed, both the product and the registered trademark ZEVALIN are owned by Biogen Idec, Inc.



Monday Dec. 10, 2007 5:00 PM	3320	#539-III	Cost of ⁹⁰Y-Ibritumomab Tiuxetan Radioimmunotherapy Versus Cost of Standard Regimens for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma in Switzerland.
Monday Dec. 10, 2007 5:00 PM	3412	#631-III	Radioimmunotherapy with ⁹⁰ Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A 'Real-Time' MBR RQ-PCR Analysis.
Monday Dec. 10, 2007 5:00 PM	3415	#634-III	Dosimetric Analysis of ⁹⁰ Y-Ibritumomab Tiuxetan (Zevalin®) Given as Consolidation of First Remission in Patients with Advanced-Stage Follicular Lymphoma in the International Phase 3 First-Line Indolent Trial (FIT).
Monday Dec. 10, 2007 5:00 PM	3426	#645-III	Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective "Dose"-Finding Study.
	4476	Publication only	Registry of RadioImmunoTherapy: Analysis of Outcomes of Recurrent or Refractory Non-Hodgkin Lymphoma Patients Treated with 90Y Ibritumomab Tiuxetan.
	4478	Publication only	Radioimmunotherapy (RIT) with ⁹⁰ Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.
	4484	Publication only	⁹⁰ Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin's Lymphoma. Multiinstitutional Argentinian Study.
	4485	Publication only	Phase I Trial of Combination Therapy with ⁹⁰ Y Ibritumomab Tiuxetan (Zevalin) and Gemcitabine in Patients with Non-Hodgkin's Lymphoma.

*CTI has entered into an agreement to acquire ZEVALIN from Biogen Idec, Inc. Completion of that acquisition is subject to certain closing conditions, including obtaining third-party consents. CTI expects to complete the acquisition in the fourth quarter of 2007, at which time CTI will acquire the rights to develop, market, and sell ZEVALIN in the United States. Until CTI's acquisition of ZEVALIN is completed, both the product and the registered trademark ZEVALIN are owned by Biogen Idec, Inc.



	4497	Publication only	⁹⁰ Y-Zevalin® (⁹⁰ Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.
	4498	Publication only	Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin's Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.
	4499	Publication only	Efficacy of ⁹⁰ Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).
	4501	Publication only	Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation –Final Analysis of a Phase II Trial of the European MCL Network.
	4505	Publication only	⁹⁰ Y-Ibritumomab as a Single Agent for De Novo or Transformed Diffuse Large B Cell Lymphoma.
	4507	Publication only	Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium 90 Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL).
	5152	Publication only	Quality Analysis of a Multidisciplinary Program Project in Radioimmunotherapy.

PIXANTRONE

Date/ Time	Abstract #	Presentation/ Poster #	Title
Monday Dec. 10, 2007 5:00 PM	3445	#664-III	CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituximab) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.

*CTI has entered into an agreement to acquire ZEVALIN from Biogen Idec, Inc. Completion of that acquisition is subject to certain closing conditions, including obtaining third-party consents. CTI expects to complete the acquisition in the fourth quarter of 2007, at which time CTI will acquire the rights to develop, market, and sell ZEVALIN in the United States. Until CTI's acquisition of ZEVALIN is completed, both the product and the registered trademark ZEVALIN are owned by Biogen Idec, Inc.